Missed Cystic Fibrosis Newborn Screening Cases Due to Immunoreactive Trypsinogen Levels Below Program Cutoffs: A National Survey of Risk Factors

Overview

Journal Int J Neonatal Screen

Date 2022 Nov 22

PMID 36412584

Authors

Martin Kharrazi

Charlene Sacramento

Anne Marie Comeau

Jaime E Hale

Michele Caggana

Denise M Kay

Rachel Lee

Brendan Reilly

John D Thompson

Samya Z Nasr

Mary Kleyn

Gary Hoffman

Mei W Baker

Colleen Clarke

Cheryl L Harris

M Christine Dorley

Hilary Fryman

Ankit Sutaria

Amy Hietala

Holly Winslow

Holly Richards

Bradford L Therrell

Affiliations

Soon will be listed here.

Abstract

Testing immunoreactive trypsinogen (IRT) is the first step in cystic fibrosis (CF) newborn screening. While high IRT is associated with CF, some cases are missed. This survey aimed to find factors associated with missed CF cases due to IRT levels below program cutoffs. Twenty-nine states responded to a U.S-wide survey and 13 supplied program-related data for low IRT false screen negative cases (CFFN) and CF true screen positive cases (CFTP) for analysis. Rates of missed CF cases and odds ratios were derived for each factor in CFFNs, and two CFFN subgroups, IRT above ("high") and below ("low") the CFFN median (39 ng/mL) compared to CFTPs for this entire sample set. Factors associated with "high" CFFN subgroup were Black race, higher IRT cutoff, fixed IRT cutoff, genotypes without two known CF-causing variants, and meconium ileus. Factors associated with "low" CFFN subgroup were older age at specimen collection, Saturday birth, hotter season of newborn dried blood spot collection, maximum ≥ 3 days laboratories could be closed, preterm birth, and formula feeding newborns. Lowering IRT cutoffs may reduce "high" IRT CFFNs. Addressing hospital and laboratory factors (like training staff in collection of blood spots, using insulated containers during transport and reducing consecutive days screening laboratories are closed) may reduce "low" IRT CFFNs.

Citing Articles

Cystic Fibrosis Screening Efficacy and Seasonal Variation in California: 15-Year Comparison of IRT Cutoffs Versus Daily Percentile for First-Tier Testing.

Sciortino S, Graham S, Bishop T, Matteson J, Carter S, Wu C Int J Neonatal Screen. 2024; 10(4).

PMID: 39584999 PMC: 11627160. DOI: 10.3390/ijns10040076.

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020-2023).

Therrell B, Padilla C, Borrajo G, Khneisser I, Schielen P, Knight-Madden J Int J Neonatal Screen. 2024; 10(2).

PMID: 38920845 PMC: 11203842. DOI: 10.3390/ijns10020038.

An Approach to Re-evaluate the Reference Cutoff of the Parameters of Newborn Screening: An Observational Study.

Patel S, Verma N, Padhi P, Shah S, Nanda R, Mohapatra E Cureus. 2023; 15(9):e45139.

PMID: 37842412 PMC: 10570011. DOI: 10.7759/cureus.45139.

Neonatal Screening for Cystic Fibrosis in Hungary-First-Year Experiences.

Xue A, Lenart I, Kincs J, Szabo H, Parniczky A, Balogh I Int J Neonatal Screen. 2023; 9(3).

PMID: 37754773 PMC: 10531581. DOI: 10.3390/ijns9030047.

Diagnostic and Communication Challenges in Cystic Fibrosis Newborn Screening.

DeCelie-Germana J, Bonitz L, Langfelder-Schwind E, Kier C, Diener B, Berdella M Life (Basel). 2023; 13(8).

PMID: 37629501 PMC: 10455801. DOI: 10.3390/life13081646.

References

Adam B, Flores S, Hou Y, Allen T, De Jesus V . Galactose-1-phosphate uridyltransferase dried blood spot quality control materials for newborn screening tests. Clin Biochem. 2014; 48(6):437-42. PMC: 4547523. DOI: 10.1016/j.clinbiochem.2014.12.009. View

Rock M, Levy H, Zaleski C, Farrell P . Factors accounting for a missed diagnosis of cystic fibrosis after newborn screening. Pediatr Pulmonol. 2011; 46(12):1166-74. PMC: 4469987. DOI: 10.1002/ppul.21509. View

Sontag M, Corey M, Hokanson J, Marshall J, Sommer S, Zerbe G . Genetic and physiologic correlates of longitudinal immunoreactive trypsinogen decline in infants with cystic fibrosis identified through newborn screening. J Pediatr. 2006; 149(5):650-657. DOI: 10.1016/j.jpeds.2006.07.026. View

Doull I, Course C, Hanks R, Southern K, Forton J, Thia L . Cystic fibrosis newborn screening: the importance of bloodspot sample quality. Arch Dis Child. 2020; 106(3):253-257. DOI: 10.1136/archdischild-2020-318999. View

Southern K, Munck A, Pollitt R, Travert G, Zanolla L, Dankert-Roelse J . A survey of newborn screening for cystic fibrosis in Europe. J Cyst Fibros. 2006; 6(1):57-65. DOI: 10.1016/j.jcf.2006.05.008. View

Marie Comeau A, Parad R, Dorkin H, Dovey M, Gerstle R, Haver K . Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics. 2004; 113(6):1573-81. DOI: 10.1542/peds.113.6.1573. View

Taccetti G, Botti M, Terlizzi V, Cavicchi M, Neri A, Galici V . Clinical and Genotypical Features of False-Negative Patients in 26 Years of Cystic Fibrosis Neonatal Screening in Tuscany, Italy. Diagnostics (Basel). 2020; 10(7). PMC: 7399885. DOI: 10.3390/diagnostics10070446. View

Farrell P, Rosenstein B, White T, Accurso F, Castellani C, Cutting G . Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008; 153(2):S4-S14. PMC: 2810958. DOI: 10.1016/j.jpeds.2008.05.005. View

Gregg R, Simantel A, Farrell P, Koscik R, Kosorok M, Laxova A . Newborn screening for cystic fibrosis in Wisconsin: comparison of biochemical and molecular methods. Pediatrics. 1997; 99(6):819-24. DOI: 10.1542/peds.99.6.819. View

10.

Adam B, Hall E, Sternberg M, Lim T, Flores S, OBrien S . The stability of markers in dried-blood spots for recommended newborn screening disorders in the United States. Clin Biochem. 2011; 44(17-18):1445-50. PMC: 4557772. DOI: 10.1016/j.clinbiochem.2011.09.010. View

11.

Rock M, Mischler E, Farrell P, Wei L, BRUNS W, Hassemer D . Newborn screening for cystic fibrosis is complicated by age-related decline in immunoreactive trypsinogen levels. Pediatrics. 1990; 85(6):1001-7. View

12.

Calvin J, Hogg S, McShane D, McAuley S, Iles R, Ross-Russell R . Thirty-years of screening for cystic fibrosis in East Anglia. Arch Dis Child. 2012; 97(12):1043-7. DOI: 10.1136/archdischild-2012-301968. View

13.

Kloosterboer M, Hoffman G, Rock M, Gershan W, Laxova A, Li Z . Clarification of laboratory and clinical variables that influence cystic fibrosis newborn screening with initial analysis of immunoreactive trypsinogen. Pediatrics. 2009; 123(2):e338-46. DOI: 10.1542/peds.2008-1681. View

14.

Rock M, Hoffman G, Laessig R, Kopish G, Litsheim T, Farrell P . Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing. J Pediatr. 2005; 147(3 Suppl):S73-7. DOI: 10.1016/j.jpeds.2005.08.004. View

15.

Therrell Jr B, Hannon W, Hoffman G, Ojodu J, Farrell P . Immunoreactive Trypsinogen (IRT) as a Biomarker for Cystic Fibrosis: challenges in newborn dried blood spot screening. Mol Genet Metab. 2012; 106(1):1-6. DOI: 10.1016/j.ymgme.2012.02.013. View

16.

Sontag M, Hammond K, Zielenski J, Wagener J, Accurso F . Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. J Pediatr. 2005; 147(3 Suppl):S83-8. DOI: 10.1016/j.jpeds.2005.08.005. View

17.

Paracchini V, Seia M, Raimondi S, Costantino L, Capasso P, Porcaro L . Cystic fibrosis newborn screening: distribution of blood immunoreactive trypsinogen concentrations in hypertrypsinemic neonates. JIMD Rep. 2013; 4:17-23. PMC: 3509858. DOI: 10.1007/8904_2011_55. View

18.

Sims E, Clark A, McCormick J, Mehta G, Connett G, Mehta A . Cystic fibrosis diagnosed after 2 months of age leads to worse outcomes and requires more therapy. Pediatrics. 2007; 119(1):19-28. DOI: 10.1542/peds.2006-1498. View